Cartesian Therapeutics (RNAC) Liabilities and Shareholders Equity (2015 - 2026)

Cartesian Therapeutics (RNAC) has 12 years of Liabilities and Shareholders Equity data on file, last reported at $288.4 million in Q1 2026.

• On a quarterly basis, Liabilities and Shareholders Equity fell 29.51% year-over-year to $288.4 million in Q1 2026; TTM through Mar 2026 was $1.3 billion, a 18.26% decrease from a year earlier, with the FY2025 full-year figure at $296.4 million, down 31.86% from the prior year.
• Liabilities and Shareholders Equity for Q1 2026 stood at $288.4 million, down from $296.4 million in the prior quarter.
• Over the last five years, Liabilities and Shareholders Equity for RNAC reached as high as $455.3 million in Q3 2024 and fell as low as $106.0 million in Q3 2023.
• Historically, Liabilities and Shareholders Equity has averaged $276.6 million across 5 years, with a median of $296.4 million in 2025.
• Across the five-year window, Liabilities and Shareholders Equity plunged 40.52% in 2023 and jumped 329.41% in 2024, its largest moves.
• Year by year, Liabilities and Shareholders Equity stood at $165.9 million in 2022, then jumped by 83.89% to $305.0 million in 2023, then soared by 42.61% to $435.0 million in 2024, then sank by 31.86% to $296.4 million in 2025, then slipped by 2.71% to $288.4 million in 2026.
• Per Business Quant data, the three most recent Liabilities and Shareholders Equity figures were $288.4 million in Q1 2026, $296.4 million in Q4 2025, and $372.7 million in Q3 2025.